Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-J?drzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, BladГ© J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, et al. N Engl J Med. 2012 May 10,366(19):1759-69. doi: 10.1056/NEJMoa1112704.

Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.

Jäger U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C, Einberger C, Drach J, Raderer M, Gaiger A, Putman M, Greil R Haematologica. 2012 Sep,97(9):1431-8. Epub 2012 Apr 17.

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.

Lang I, Inbar MJ, KahГЎn Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Messinger D, Brodowicz T, Zielinski C. Eur J Cancer. 2012 Nov,48(17):3140-9. doi: 10.1016/j.ejca.2012.04.022. Epub 2012 May 26.

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).

Aapro M, Molassiotis A, Dicato M, PelГЎez I, RodrГ­guez-Lescure ГЃ, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F Ann Oncol. 2012 Aug,23(8):1986-92. Epub 2012 Mar 6.

Anaplastic large cell lymphoma: the current state of play from a European prospective as presented at the second annual meeting of the European Research Initiative on ALCL, 27-28 June 2011.

Merkel O, Kenner L, Turner SD. Leukemia. Dec,25(12):1795-6. doi: 10.1038/leu.2011.295.

Infusion reactions to the chimeric EGFR inhibitor cetuximab–change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.

Resch G, Schaberl-Moser R, Kier P, Kopetzky G, Scheithauer W, Sliwa T, Greil R, Nösslinger T, Mayrbäurl B, Thaler J. Ann Oncol. 2011 Feb,22(2):486-7. doi: 10.1093/annonc/mdq744. Epub 2011 Jan 13.

Preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with newly diagnosed primary operable cT₃NxM0 low rectal cancer: a phase II study.

Ofner D, Devries AF, Schaberl-Moser R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp KS, Fastner G, Keil F, Eisterer W, Jäger R, Offner F, Gnant M, Thaler J Strahlenther Onkol. 2011 Feb,187(2):100-7. doi: 10.1007/s00066-010-2182-6. Epub 2011 Jan 21.

R-CHOP plus thalidomide for previously untreated patients with mantle cell lymphoma (AGMT NHL-11 trial)

Drach, J, Hopfinger, G, Fridrik, M, Greil, R, Thaler, J, Willenbacher, W, Lang, A, Jager, U, Raderer, M ONKOLOGIE. 2011, 34: 75-75.

Lower incidence of BCR-ABL mutations and improved molecular response kinetics in newly diagnosed CML patients treated with nilotinib compared with imatinib

Muller, MC, le Coutre, P, Gattermann, N, Scheid, C, Al-Ali, HK, Ottmann, OG, Duyster, J, Blumenstengel, K, Brummendorf, TH, Greil, R, Chalandon, Y, Valent, P, Stegelmann, F, Kneba, M, Schafhausen, P, Saussele, S, Frank, O, Larson, RA, Saglio, G, Hochhaus, A, Lange, T ONKOLOGIE. 2011, 34: 266-266.

62-Month follow-up of ABCSG-12: Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer

Gnant, M, Mlineritsch, B, Stoeger, H, Luschin-Ebengreuth, G, Poestlberger, S, Steger, G, Jakesz, R, Singer, C, Eidtmann, H, Greil, R BONE. 2011, 48(1): S17-S17.